Abbott Laboratories (NYSE:ABT) Stock Holdings Boosted by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 198,237 shares of the healthcare product maker’s stock after acquiring an additional 874 shares during the period. Abbott Laboratories makes up 2.4% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 10th biggest holding. Marble Harbor Investment Counsel LLC’s holdings in Abbott Laboratories were worth $20,599,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in ABT. Unique Wealth Strategies LLC purchased a new position in Abbott Laboratories during the second quarter worth about $28,000. Redmont Wealth Advisors LLC acquired a new position in Abbott Laboratories during the 1st quarter worth approximately $30,000. Richardson Financial Services Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $29,000. Transcendent Capital Group LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $29,000. Finally, True Wealth Design LLC grew its holdings in Abbott Laboratories by 1,677.8% during the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after acquiring an additional 302 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.10% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Abbott Laboratories in a research report on Tuesday, June 4th. The Goldman Sachs Group began coverage on shares of Abbott Laboratories in a research report on Thursday, May 30th. They set a “buy” rating and a $121.00 target price on the stock. Citigroup lifted their price target on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Evercore ISI dropped their price objective on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, Edward Jones downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.80.

Abbott Laboratories Trading Down 0.4 %

Abbott Laboratories stock opened at $116.40 on Monday. The stock has a 50-day moving average price of $109.24 and a 200 day moving average price of $108.57. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The stock has a market cap of $202.49 billion, a PE ratio of 36.26, a P/E/G ratio of 2.90 and a beta of 0.72. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The business had revenue of $10.38 billion during the quarter, compared to analyst estimates of $10.37 billion. During the same quarter in the previous year, the business posted $1.08 earnings per share. The company’s revenue was up 4.0% on a year-over-year basis. Equities research analysts predict that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.